Highbridge Capital Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Highbridge Capital Management’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-2,300	Closed	-$245K	–	1873
2016 Q2	$245K	Sell	2,300 -1,400	-38%	-$163K	﹤0.01%	1149
2016 Q1	$423K	Buy	+3,700	New	+$434K	0.01%	1043
2015 Q4	–	Sell	-4,200	Closed	-$377K	–	2017
2015 Q3	$377K	Buy	+4,200	New	+$443K	0.01%	1149

Other funds holding CBPO

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Highbridge Capital Management's CBPO Position: Q4 2016 in Review

Highbridge Capital Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q4 2016, closing a stake of 27,669 shares — an estimated $3.44M sold.

Highbridge Capital Management first reported a position in CBPO in Q3 2014 and held it in 8 quarters. The position peaked at $3.44M in Q3 2016. 143 funds tracked by Wall St. Rank hold CBPO as of Q4 2016.

Highbridge Capital Management reported no remaining China Biologic Products Holdings, Inc. position as of Q4 2016 after selling out during the quarter.
Highbridge Capital Management sold 27,669 China Biologic Products Holdings, Inc. shares in Q4 2016, an estimated $3.44M.
Highbridge Capital Management first reported a position in China Biologic Products Holdings, Inc. in Q3 2014 and held it in 8 quarters.
Highbridge Capital Management's China Biologic Products Holdings, Inc. position peaked at $3.44M in Q3 2016.
143 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.